BBHC
FATE icon

Brown Brothers Harriman & Co’s Fate Therapeutics FATE Stock Holding History

Brown Brothers Harriman & Co’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-79
Closed -$2K – 1343
2022
Q3 		$2K Buy
+79
New +$2.28K ﹤0.01% 1418

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Brown Brothers Harriman & Co's FATE Position: Q4 2022 in Review

Brown Brothers Harriman & Co sold out of Fate Therapeutics (FATE) in Q4 2022, closing a stake of 79 shares — an estimated $2K sold.

Brown Brothers Harriman & Co first reported a position in FATE in Q3 2022 and held it in 1 quarter. The position peaked at $2K in Q3 2022. 227 funds tracked by Wall St. Rank hold FATE as of Q4 2022.

  • Brown Brothers Harriman & Co reported no remaining Fate Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 79 Fate Therapeutics shares in Q4 2022, an estimated $2K.
  • Brown Brothers Harriman & Co first reported a position in Fate Therapeutics in Q3 2022 and held it in 1 quarter.
  • Brown Brothers Harriman & Co's Fate Therapeutics position peaked at $2K in Q3 2022.
  • 227 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2022.

Based on Brown Brothers Harriman & Co's 13F filing for Q4 2022, filed 9 Feb 2023.